Pancreatic cancer is deadly and difficult to treat. A new pill could change that
Revolution Medicines’ new KRAS-targeting pill, daraxonrasib, showed promising early trial results in pancreatic cancer patients, nearly doubling survival rates to 13.2 months compared to standard chemotherapy. The drug, targeting mutations found in over 90% of pancreatic ductal adenocarcinoma cases, also shrank tumors in a third of patients with the RAS G12 mutation but caused severe side effects in 30% of participants.
A new drug developed by Revolution Medicines, called daraxonrasib, has generated cautious optimism among physicians and researchers for treating pancreatic cancer, one of the deadliest and most difficult-to-treat cancers. The pill targets the KRAS gene, which is mutated in over 90% of pancreatic ductal adenocarcinoma (PDAC) cases, as well as 40-45% of colorectal cancers and up to 30% of non-small cell lung cancers. KRAS mutations have long been considered 'undruggable,' but daraxonrasib marks a potential breakthrough in oncology. Preliminary trial data released in April revealed that patients treated with daraxonrasib as a second-line therapy survived an average of 13.2 months, nearly double the 6.7 months seen with standard chemotherapy. Among 168 PDAC patients, 26 had the RAS G12 mutation, the most common KRAS variant in pancreatic cancer. Over one-third of these patients experienced tumor shrinkage by 30% or more on CT scans, and their median survival time was 13.1 months, with progression-free survival lasting 8.5 months. The drug’s efficacy comes with notable side effects: about 30% of patients faced severe reactions, including rashes in 90% of cases, along with diarrhea, mouth inflammation, or gastrointestinal issues in nearly half. Experts like Dr. Emil Lou, a professor at the University of Minnesota Medical School, described the survival extension as 'extraordinary,' though further data from Revolution Medicines—set to be released—will be critical in assessing long-term benefits. Daraxonrasib’s success hinges on its ability to inhibit KRAS, a gene linked to up to 20% of all cancers. When dysregulated, KRAS overstimulates cell growth, driving tumor development. Dr. Despina Siolas of Weill Cornell Medical College noted that the drug’s approval could 'open up the whole field' of cancer treatment, potentially extending its applications beyond pancreatic cancer. The trial results suggest a potential shift in how advanced pancreatic cancer is managed, though challenges like side effects and broader applicability remain under review.
This content was automatically generated and/or translated by AI. It may contain inaccuracies. Please refer to the original sources for verification.